Equities analysts predict that Emergent Biosolutions, Inc. (NYSE:EBS) will announce sales of $175.41 million for the current quarter, Zacks reports. Two analysts have provided estimates for Emergent Biosolutions’ earnings, with the highest sales estimate coming in at $179.71 million and the lowest estimate coming in at $171.10 million. Emergent Biosolutions posted sales of $151.66 million in the same quarter last year, which would indicate a positive year over year growth rate of 15.7%. The firm is scheduled to report its next quarterly earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Emergent Biosolutions will report full-year sales of $175.41 million for the current year, with estimates ranging from $516.80 million to $547.30 million. For the next year, analysts anticipate that the firm will report sales of $634.88 million per share, with estimates ranging from $600.04 million to $691.80 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Emergent Biosolutions.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm had revenue of $149.43 million during the quarter, compared to the consensus estimate of $124.55 million. During the same quarter in the prior year, the company earned $0.56 EPS. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year.

Several research firms have commented on EBS. Zacks Investment Research raised Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Wednesday, October 25th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $43.00 price target (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Finally, BidaskClub raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Emergent Biosolutions presently has an average rating of “Buy” and a consensus target price of $45.00.

Emergent Biosolutions (EBS) traded up $0.29 during trading on Friday, reaching $40.86. The company’s stock had a trading volume of 247,000 shares, compared to its average volume of 324,467. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37. The firm has a market cap of $1,678.58, a PE ratio of 21.45, a price-to-earnings-growth ratio of 1.12 and a beta of 1.22. Emergent Biosolutions has a 12-month low of $25.96 and a 12-month high of $44.86.

In other Emergent Biosolutions news, Director Jerome M. Hauer sold 10,776 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total value of $386,104.08. Following the completion of the transaction, the director now owns 29,421 shares of the company’s stock, valued at approximately $1,054,154.43. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director George A. Joulwan sold 14,251 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $41.24, for a total value of $587,711.24. Following the completion of the transaction, the director now directly owns 34,323 shares of the company’s stock, valued at $1,415,480.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 225,986 shares of company stock valued at $8,929,278. Insiders own 16.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of EBS. Northern Trust Corp raised its holdings in shares of Emergent Biosolutions by 47.2% in the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock worth $30,747,000 after buying an additional 290,863 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Emergent Biosolutions by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock worth $109,574,000 after buying an additional 238,194 shares in the last quarter. State Street Corp raised its holdings in shares of Emergent Biosolutions by 17.2% in the 1st quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock worth $42,180,000 after buying an additional 213,500 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Emergent Biosolutions by 7.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock worth $74,795,000 after buying an additional 152,029 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in shares of Emergent Biosolutions by 26.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 669,617 shares of the biopharmaceutical company’s stock worth $22,707,000 after buying an additional 138,611 shares in the last quarter. 85.98% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “$175.41 Million in Sales Expected for Emergent Biosolutions, Inc. (EBS) This Quarter” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/11/175-41-million-in-sales-expected-for-emergent-biosolutions-inc-ebs-this-quarter.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.